Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.
Fernando
Suran L
SL
PaLMS Immunorheumatology Laboratory, Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Reserve Rd, St. Leonards, Sydney, NSW 2065, Australia. sfernando@nsccahs.health.nsw.gov.au
Broadfoot
Andrew J
AJ
D000328:Adult; D000483:Alleles; D000493:Allopurinol / Q000009:adverse effects*; D000927:Anticonvulsants / Q000009:adverse effects; D044466:Asian People / Q000235:genetics; D002220:Carbamazepine / Q000009:adverse effects; D002681:China; D016572:Cyclosporine / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006074:Gout Suppressants / Q000009:adverse effects*; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007637:Keratoconjunctivitis / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000209:etiology*; D014526:Urethritis / Q000139:chemically induced / Q000188:drug therapy
D000927:Anticonvulsants; D006074:Gout Suppressants; D015235:HLA-B Antigens; D007166:Immunosuppressive Agents; D002220:Carbamazepine; D000493:Allopurinol; D016572:Cyclosporine